Cat. No. 2568
Biological ActivityMyelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. Produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. Induces strong T and B cell responses and is highly encephalitogenic.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Zhang et al (2004) T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6xSJL) F1 mice. J.Neuroimmunol. 148 1. PMID: 14975581.
Slavin et al (1998) Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28 109. PMID: 9771980.
Ichikawa et al (1996) Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J.Immunol. 157 919. PMID: 8752946.
If you know of a relevant reference for MOG (35-55) please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses MOG (35-55) from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MOG (35-55), supplier, Encephalitogenic, myelin, oligodendrocyte, glycoprotein, fragment, Neuronal, Metabolism, Tocris Bioscience, Neuronal Metabolism products
Find multiple products by catalog number
New Products in this Area
RAD51 recombinase inhibitorPCNA I1
PCNA inhibitorPladienolide B
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.